ELSEVIER

Atherosclerosis 115 (1995) 273–275

ATHEROSCLEROSIS

Author index

Volume 115 (1995)

Amerio, P., see Porreca, E. **115**, 181
Andersen, H.O., see Holm, P. **115**, 191
Areias, A.J., see Raal, F.J. **115**, 9
Arveiler, D., see Marques-Vidal, P. **115**, 225
Auerbach, B.J., B.R. Krause, C.L. Bisgaier, R.S. Newton, Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: Atorvastatin versus lovastatin **115**, 173
Aviram, M., see Keidar, S. **115**, 201

Bingham, A., see Marques-Vidal, P. **115**, 225
Birkenhäger, J.C., see Jansen, H. **115**, 255
Bisgaier, C.L., see Auerbach, B.J. **115**, 173
Boykow, G., see Salisbury, B.G. **115**, 45
Braun, P., see Park, J.-W. **115**, 1
Brousseau, M.E., E.J. Schaefer, A.F. Stucchi, J. Osada, D.B. Vespa, J.M. Ordovas, R.J. Nicolosi, Diets enriched in unsaturated fatty acids enhance apolipoprotein A-I catabolism but do not affect either its production or hepatic mRNA abundance in cynomolgus monkeys **115**, 107
Burnett, D.A., see Salisbury, B.G. **115**, 45
Burrier, R.E., see Salisbury, B.G. **115**, 45

Cambien, F., see Marques-Vidal, P. **115**, 225
Cambou, J.-P., see Marques-Vidal, P. **115**, 225
Caplen, M.A., see Salisbury, B.G. **115**, 45
Castle, C.K., see Lin, A.H. **115**, 85
Clader, J.W., see Salisbury, B.G. **115**, 45
Clavey, V., see Gottrand, F. **115**, 233
Clemmons, A.L., see Salisbury, B.G. **115**, 45
Compton, D.S., see Salisbury, B.G. **115**, 45
Conti, P., see Porreca, E. **115**, 181
Cuccurullo, F., see Porreca, E. **115**, 181

Davis, H.R., see Salisbury, B.G. **115**, 45
Di Febbo, C., see Porreca, E. **115**, 181
Drózdz, M., see Toborek, M. **115**, 217
Durrington, P.N., see Mackness, M.I. **115**, 243

Evans, A., see Marques-Vidal, P. **115**, 225

Farriaux, J.-P., see Gottrand, F. **115**, 233
Feliciani, C., see Porreca, E. **115**, 181
Feuerstein, G.Z., see Wang, X. **115**, 89
Fowkes, F.G.R., see Smith, F.B. **115**, 35
Fruchart, J.-C., see Gottrand, F. **115**, 233

Gallagher, J.J., N.B. Myant, The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein **115**, 263
Ghanem, H., see Jansen, H. **115**, 255
Gorog, P., I.B. Kovacs, Lipid peroxidation by activated platelets: A possible link between thrombosis and atherogenesis **115**, 121
Gottrand, F., V. Clavey, J.-C. Fruchart, J.-P. Farriaux, Lipoprotein pattern and plasma lecithin cholesterol acyl transferase activity in children with Alagille syndrome **115**, 233
Grobelny, J., see Tarnawski, R. **115**, 27
Gu, J.-L., see Wang, X. **115**, 89
Gylling, H., H. Relas, T.A. Miettinen, Postprandial vitamin A and squalene clearances and cholesterol synthesis off and on lovastatin treatment in type III hyperlipoproteinemia **115**, 17

Hansen, B.F., see Holm, P. **115**, 191
Herrmann, R.A., see Malinauskas, R.A. **115**, 147
Holm, P., H.O. Andersen, B.G. Nordestgaard, B.F. Hansen, K. Kjeldsen, S. Stender, Effect of oestrogen replacement therapy on development of experimental arteriosclerosis: A study in transplanted and balloon-injured rabbit aortas **115**, 191
Hoos, L.M., see Salisbury, B.G. **115**, 45
Hoppichler, F., C. Sandholzer, R. Moncayo, G. Utermann, H.G. Kraft, Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels **115**, 65
Hoffman, A., see Keidar, S. **115**, 201

Ivey, J., M.R. Roach, R.G. Kratky, A new probability mapping method to describe the development of atherosclerotic lesions in cholesterol-fed rabbits **115**, 73

Jansen, H., H. Ghanem, J.H.S.A.M. Kuypers, J.C. Birkenhäger, Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass pattern B **115**, 255

Kaplan, M., see Keidar, S. **115**, 201
Katan, M.B., see van Tol, A. **115**, 129
Keidar, S., M. Kaplan, A. Hoffman, M. Aviram, Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins **115**, 201
Kesäniemi, Y.A., see Ukkola, O. **115**, 99
Kjeldsen, K., see Holm, P. **115**, 191
Kopieczna-Grzebieniak, E., see Toborek, M. **115**, 217
Kovacs, I.B., see Gorog, P. **115**, 121
Kraft, H.G., see Hoppichler, F. **115**, 65
Kratky, R.G., see Ivey, J. **115**, 73
Krause, B.R., see Auerbach, B.J. **115**, 173
Kuypers, J.H.S.A.M., see Jansen, H. **115**, 255

Lee, A.J., see Smith, F.B. **115**, 35
Lin, A.H., C.K. Castle, G.W. Melchior, K.R. Marotti, The effect of population density on the development of experimental atherosclerosis in female mice **115**, 85
Lowe, G.D.O., see Smith, F.B. **115**, 35
Luc, G., see Marques-Vidal, P. **115**, 225
Lysko, P.G., see Wang, X. **115**, 89

Mackness, M.I., P.N. Durrington, HDL, its enzymes and its potential to influence lipid peroxidation **115**, 243
Malinauskas, R.A., R.A. Herrmann, G.A. Truskey, The distribution of intimal white blood cells in the normal rabbit aorta **115**, 147
Marotti, K.R., see Lin, A.H. **115**, 85
Marques-Vidal, P., J.-P. Cambou, V. Nicaud, G. Luc, A. Evans, D. Arveiler, A. Bingham, F. Cambien, Cardiovascular risk factors and alcohol consumption in France and Northern Ireland **115**, 225
May, E., see Park, J.-W. **115**, 1
McGregor, D.G., see Salisbury, B.G. **115**, 45
Melchior, G.W., see Lin, A.H. **115**, 85
Merz, M., see Park, J.-W. **115**, 1
Miettinen, T.A., see Gylling, H. **115**, 17
Miettinen, T.A., see Vanhanen, H.T. **115**, 135
Mincione, G., see Porreca, E. **115**, 181
Moncayo, R., see Hoppichler, F. **115**, 65
Myant, N.B., see Gallagher, J.J. **115**, 263

Neri, M., see Porreca, E. **115**, 181
Newton, R.S., see Auerbach, B.J. **115**, 173
Nicaud, V., see Marques-Vidal, P. **115**, 225
Nicolosi, R.J., see Brousseau, M.E. **115**, 107
Nordestgaard, B.G., see Holm, P. **115**, 191

Ordovas, J.M., see Brousseau, M.E. **115**, 107
Osada, J., see Brousseau, M.E. **115**, 107

Park, J.-W., M. Vermeltfoort, P. Braun, E. May, M. Merz, Regression of transplant coronary artery disease during chronic HELP therapy: A case study **115**, 1
Porreca, E., P. Conti, C. Feliciani, C. Di Febbo, M. Reale, G. Mincione, M. Neri, P. Amerio, F. Cuccurullo, Cysteinyl-leukotriene D_4 induced IL-1β expression and release in rat vascular smooth muscle cells **115**, 181

Raal, F.J., A.J. Areias, R. Waisberg, M. von Arb, Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia **115**, 9
Rainwater, D.L., Genetic basis for multimodal relationship between apolipoprotein (a) size and lipoprotein (a) concentration in Mexican-Americans **115**, 165
Reale, M., see Porreca, E. **115**, 181
Relas, H., see Gylling, H. **115**, 17
Roach, M.R., see Ivey, J. **115**, 73
Rumley, A., see Smith, F.B. **115**, 35

Salisbury, B.G., H.R. Davis, R.E. Burrier, D.A. Burnett, G. Boykow, M.A. Caplen, A.L. Clemmons, D.S. Compton, L.M. Hoos, D.G. McGregor, R. Schnitzer-Polokoff, A.A. Smith, B.C. Weig, D.L. Zilli, J.W. Clader, E.J. Sybertz, Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461 **115**, 45
Salmela, P.I., see Ukkola, O. **115**, 99
Sandholzer, C., see Hoppichler, F. **115**, 65
Savolainen, M.J., see Ukkola, O. **115**, 99
Schaefer, E.J., see Brousseau, M.E. **115**, 107
Scheek, L.M., see van Tol, A. **115**, 129
Schnitzer-Polokoff, R., see Salisbury, B.G. **115**, 45
Smith, A.A., see Salisbury, B.G. **115**, 45
Smith, F.B., A.J. Lee, A. Rumley, F.G.R. Fowkes, G.D.O. Lowe, Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease **115**, 35
Stender, S., see Holm, P. **115**, 191
Stucchi, A.F., see Brousseau, M.E. **115**, 107
Sybertz, E.J., see G. Salisbury, B.G. **115**, 45

Tarnawski, R., see Tarnawski, R. **115**, 27
Tarnawski, R., R. Tarnawski, J. Grobelny, Changes in elastin in human atherosclerotic aorta: Carbon-13 magic angle sample-spinning NMR studies **115**, 27
Toborek, M., E. Kopieczna-Grzebieniak, M. Drózdz, M. Wieczorek, Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits **115**, 217
Truskey, G.A., see Malinauskas, R.A. **115**, 147

Ukkola, O., M.J. Savolainen, P.I. Salmela, K. von Dickhoff, Y.A. Kesäniemi, DNA polymorphisms at the lipoprotein lipase gene are associated with macroangiopathy in type 2 (non-insulin-dependent) diabetes mellitus **115**, 99
Utermann, G., see Hoppichler, F. **115**, 65

van Gent, T., see van Tol, A. **115**, 129
van Tol, A., P.L. Zock, T. van Gent, L.M. Scheek, M.B. Katan, Dietary *trans* fatty acids increase serum cholesterylester transfer protein activity in man **115**, 129
Vanhanen, H.T., T.A. Miettinen, Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination **115**, 135

Vermeltfoort, M., see Park, J.-W. **115**, 1
Vespa, D.B., see Brousseau, M.E. **115**, 107
von Arb, M., see Raal, F.J. **115**, 9
von Dickhoff, K., see Ukkola, O. **115**, 99

Waisberg, R., see Raal, F.J. **115**, 9
Wang, X., G.Z. Feuerstein, J.-L. Gu, P.G. Lysko, T.-L. Yue, Interleukin-1β induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells **115**, 89
Weig, B.C., see Salisbury, B.G. **115**, 45
Wieczorek, M., see Toborek, M. **115**, 217

Yue, T.-L., see Wang, X. **115**, 89

Zilli, D.L., see Salisbury, B.G. **115**, 45
Zock, P.L., see van Tol, A. **115**, 129

ELSEVIER

Atherosclerosis 115 (1995) 277–278

ATHEROSCLEROSIS

Subject index

Volume 115 (1995)

Alagille syndrome **115**, 233
Alcohol consumption **115**, 225
Angiotensin II **115**, 201
Antioxidative enzymes **115**, 217
Apo(a) alleles **115**, 165
Apo(a) phenotypes **115**, 165
Apolipoprotein A-I **115**, 107
Apolipoprotein(a) phenotypes **115**, 65
Apolipoproteins **115**, 225
Arterial wall **115**, 191
Atherogenesis **115**, 181
Atherosclerosis **115**, 27, 73, 85, 89, 121, 129, 147, 217
Atorvastatin **115**, 173
Autoantibodies **115**, 255

Balloon injury **115**, 191

Cardiovascular risk factors **115**, 35
Casein fed rabbit **115**, 173
C57BL/6 mice **115**, 85
Children **115**, 233
Cholestanol **115**, 135
Cholesterol **115**, 99
Cholesterol absorption **115**, 45
Cholesterol absorption and synthesis **115**, 135
Cholesterol precursors **115**, 135
Cholesterol synthesis **115**, 17
Cholesterol-fed rabbits **115**, 191
Cholesterylester transfer protein (CETP) **115**, 129
Coronary heart disease **115**, 129, 99
CP-MAS NMR **115**, 27
Cynomolgus monkeys **115**, 107
Cysteinyl-leukotrienes **115**, 181

Dietary *trans* fatty acids **115**, 129
Dysbetalipoproteinemia **115**, 17

ELAM-1 **115**, 89
Elastase **115**, 27
Elastin **115**, 27
Endothelial cells **115**, 147
Endothelium **115**, 191
Experimental arteriosclerosis **115**, 191

Familial defective apo B-100 **115**, 263
Familial hypercholesterolaemia **115**, 9
Fatty acids **115**, 107
Fecal steroids **115**, 135
Female **115**, 85
Fibrinolysis **115**, 35
Fibro-fatty lesion **115**, 73
Flow dividers **115**, 147

Gemfibrozil **115**, 135
Genetics **115**, 99

Haemostasis **115**, 225
Hamsters **115**, 45
Häutchen preparations **115**, 147
HDL **115**, 243
HDL-associated enzymes **115**, 243
Hepatic apolipoprotein A-I mRNA **115**, 107
High density lipoproteins **115**, 107
High-density lipoproteins (HDL) **115**, 129
HMG-CoA reductase inhibitors **115**, 173
Hypercholesterolemia **115**, 45
Hyperthyroidism **115**, 65

ICAM-1 **115**, 89
IL-1 **115**, 181
IL-1β **115**, 89
Intestines **115**, 45
Intrahepatic cholestasis **115**, 233

LDL **115**, 243
LDL fractional catabolic rate **115**, 173
LDL oxidation **115**, 201
LDL production **115**, 173
LDL subclasses **115**, 255
LDL turnover **115**, 173
LDL-apheresis **115**, 1
Lecithin cholesterol acyl transferase **115**, 233

Lecithin:cholesterol acyltransferase (LCAT) **115**, 129
Lesion development **115**, 73
Lipid oxidation **115**, 9
Lipid peroxidation **115**, 121, 243
Lipoprotein lipase **115**, 99
Lipoprotein particles **115**, 225
Lipoprotein(a) **115**, 65
Lipoprotein(a) metabolism **115**, 65
Lipoprotein(a) plasma concentration **115**, 65
Lipoprotein-X **115**, 233
Lipoproteins **115**, 225, 233
Liver **115**, 45
Lovastatin **115**, 17, 173
Low density lipoprotein **115**, 9
Low-density lipoproteins **115**, 263
Low-density lipoproteins (LDL) **115**, 129
Lp(a) **115**, 165

Macroangiopathy **115**, 99
Macrophages **115**, 147, 201
Metabolism **115**, 107
Methionine **115**, 217
Mexican Americans **115**, 165
Monocytes **115**, 147

Non-insulin-dependent diabetes mellitus **115**, 99
Nonhuman primates **115**, 45

Oestrogen replacement therapy **115**, 191
Orifice **115**, 73
Oxidation **115**, 255
Oxidative modification **115**, 243
Oxidative stress **115**, 217

Peripheral arterial disease **115**, 35
Permeability **115**, 147
Plant sterols **115**, 135
Plasma cholesterol **115**, 85, 173
Plasminogen activator inhibitor **115**, 35
Platelets **115**, 121
Polar mapping **115**, 73
Polymorphism **115**, 165
Population density **115**, 85
Postprandial lipoproteins **115**, 17
Pravastatin **115**, 135
Probability mapping **115**, 73
Psychosocial **115**, 85

Quantitative coronary angiography **115**, 1

Rabbit **115**, 73, 147
Rabbits **115**, 217
Rats **115**, 45
Receptor-binding **115**, 263
Regression **115**, 1

Squalene **115**, 17

Tissue-plasminogen activator **115**, 35
Transplant coronary artery disease **115**, 1
Transplantation **115**, 191
Triglycerides **115**, 99

Vascular smooth muscle cell **115**, 89
Vascular smooth muscle cells **115**, 181
VCAM-1 **115**, 89
Very-low-density lipoprotein remnants **115**, 263
Vitamin A **115**, 17
Vitamin E **115**, 9

White blood cells **115**, 147